ALLK Stock Data and Insider Activity
ALLK - Allakos Inc. Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
  
     
Chart and Financial Data provided by TradingView
Whale Activity

Recently reported position changes by institutional investors

Senate Trading

Recent trades by U.S. Senators

No data for this ticker
House Trading

Recent trades by U.S. Representatives

Date Rep. Type
6/16/2022 Christopher L. Jacobs Purchase
Insider Trading

Quarterly net insider trading by a company's directors and management

Corporate Flights

Flights by private jets registered to ALLK

No data for this ticker
Government Contracts

Federal grants, loans, and purchases. Click on a date for more info.

No data for this ticker
WallStreetBets